SAGE Therapeutics Inc at BMO Capital Markets Prescription for Success Healthcare Conference Transcript
Hi, everyone. I'm Gary Nachman, the specialty pharma analyst at BMO. We're very excited to have Sage management with us, Al Robichaud, Chief Scientific Officer; and Kimi Iguchi, CFO. So we'll be able to cover all aspects of the pipeline with Al, even the early-stage programs and, of course, the commercial developments with the upcoming launch of ZULRESSO that Kimi will be able to address. So it's really great to have you guys here during this very exciting time for the company. I was just saying that Jeff is probably a little busy with the launch of the new products.
Yes. Absolutely. The whole company.
Good. We'll get to ZULRESSO after, of course, but let's start with SAGE-217, Al, where most of the investor focus has been. So looking ahead to the Phase III MDD study readout in either 4Q of this year or 1Q of next year. What are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |